Jason DamianoChief Scientific Officer at Appia BioSpeaker
Profile
Dr. Jason Damiano is the Chief Scientific Officer of Appia Bio, leading research focused on a pipeline of off-the-shelf engineered CAR-NKT and CAR-gamma delta T cell therapies for oncology and autoimmune disease applications. Prior to joining Appia Bio, Jason led successful innovative drug discovery and biology groups at Unity Biotechnology, Achaogen, Igenica and the Novartis Institutes for BioMedical Research. Jason completed his Ph.D. training in cancer biology & pharmacology at the University of Arizona and trained as a postdoc in apoptosis & inflammation research under John Reed at the Sanford Burnham Prebys Medical Research Institute.
Agenda Sessions
Armored HSC-Derived CAR-iNKT: A Differentiated Platform To Target Solid Tumors
, 4:00pmView Session